Actively Recruiting
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
Led by Fourth Affiliated Hospital of Guangxi Medical University · Updated on 2023-02-21
108
Participants Needed
1
Research Sites
260 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study carried out a prospective, randomized, controlled clinical study under the background of intensity-modulated radiation therapy and three-dimensional afterloading therapy. By comparing simultaneous intensity-modulated radiotherapy and chemotherapy combined with adjuvant chemotherapy and simultaneous intensity-modulated radiotherapy and chemotherapy alone, based on the 2018 FIGO staging The clinical efficacy of locally advanced cervical cancer further clarifies the role of adjuvant chemotherapy in locally advanced cervical cancer.
CONDITIONS
Official Title
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Cervical cancer confirmed by histopathology including squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- FIGO stage IB3, IIA2, IIB-IVA according to 2018 staging
- Locally advanced cervical cancer patients who received standard concurrent intensity-modulated chemoradiotherapy followed by three-dimensional afterloading treatment with complete response
- Aged 18 to 75 years
- Performance status score of 0 to 1
- Serum hemoglobin >= 100 x 10^9/L, platelets >= 100000/μL, neutrophils >= 1500/μL
- Serum creatinine <= 1.5 times upper normal limit or creatinine clearance >= 60 ml/min
- Serum bilirubin <= 1.5 times upper normal limit, AST and ALT <= 1.5 times upper normal limit
- Signed informed consent showing understanding of study policies
- Estimated total survival greater than 6 months
You will not qualify if you...
- Patients with locally advanced cervical cancer who did not achieve complete response after chemoradiotherapy and three-dimensional afterloading
- Patients who have received neoadjuvant chemotherapy and surgery
- Patients with cognitive impairment
- Patients with any distant metastases
- Patients with any other malignancy within the past 5 years
- Conditions contraindicating chemoradiotherapy such as active infection, recent myocardial infarction, symptomatic heart disease, immunosuppressive therapy
- Pregnant or lactating women or fertile women not using contraception
- Severe bone marrow dysfunction
- Patients with bleeding tendency
- Drug abusers or alcohol addicts
- Known severe allergic reactions (3rd or 4th degree) to any study treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
the Fourth Affiliated Hospital of Guangxi Medical University
Liuzhou, Guangxi, China, 545005
Actively Recruiting
Research Team
H
Huang haixin
CONTACT
F
Feng chengjun
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here